Antonio Guglietta

USPTO Granted Patents = 21 (Patent Applications = 12)

CIPO Patents = 6

EPO Patents = 15 (Patent Applications = 14)

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Sant Joan Despí, ES (2008)
Barcelona, ES (2008 - 2018)
Molins de Rei, ES (2011 - 2018)

Company Filing History:

14 out of 47

Ferrer Internacional, S.a.

patents

4 out of 6

Ferrer International, S.a.

Years Active: 2008-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240875 - Use of FCRN antagonists for treatment of generalized myasthenia gravis (2025-03-04),

2. 10072000 - Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines (2018-09-11),

3. 10022363 - Pharmaceutical topical compositions (2018-07-17),

4. 9399014 - Pharmaceutical topical compositions (2016-07-26),

5. 9180200 - Pharmaceutical topical compositions (2015-11-10),

6. 8993562 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions (2015-03-31),

7. 8530482 - Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates (2013-09-10),

8. 8354430 - Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine (2013-01-15),

9. 8338436 - [object Object] (2012-12-25),

10. 8273753 - Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide (2012-09-25),

11. 8227501 - [object Object] (2012-07-24),

12. 8207197 - Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine (2012-06-26),

13. 8158632 - [object Object] (2012-04-17),

14. 8153789 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions (2012-04-10),

15. 8039476 - Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide (2011-10-18),

Title: Antonio Guglietta: Innovator in Medical Treatments

Introduction: Antonio Guglietta, based in Barcelona, ES, is a distinguished inventor with an impressive portfolio of 21 patents. His work is primarily focused on developing innovative treatments for various medical conditions, showcasing his commitment to advancing healthcare.

Latest Patents: Among Guglietta's latest patents is a method for utilizing FcRn antagonists in the treatment of generalized myasthenia gravis. This novel approach involves administering an effective amount of an isolated FcRn antagonist, which demonstrates increased affinity and reduced pH dependence compared to the native Fc region. Another significant patent addresses insomnia treatment through the use of halogenated pyrazolo[1,5-a]pyrimidines. This invention details compounds that can treat or prevent anxiety, epilepsy, and sleep disorders, while also facilitating sedation-hypnosis, anesthesia, and muscle relaxation.

Career Highlights: Throughout his career, Antonio has collaborated with notable companies such as Ferrer Internacional, S.A. and Ferrer International, S.A. His role in these organizations has been instrumental in developing groundbreaking medical innovations that stand to improve patient outcomes significantly.

Collaborations: Antonio Guglietta has worked alongside esteemed colleagues, including Albert Palomer and Luis Anglada. Their combined expertise has fostered an environment of creativity and innovation, leading to meaningful advancements in pharmaceutical science.

Conclusion: Antonio Guglietta exemplifies the spirit of innovation in the medical field. With a remarkable number of patents and a dedicated career in research and development, he continues to make significant contributions to the treatment of complex health conditions. His work not only demonstrates technical ingenuity but also a profound commitment to enhancing the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.